Last reviewed · How we verify
SCTB35 injection
At a glance
| Generic name | SCTB35 injection |
|---|---|
| Also known as | none other names |
| Sponsor | Sinocelltech Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of SCTB35 in Patients with Systemic Lupus Erythematosus (PHASE1, PHASE2)
- A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCTB35 injection CI brief — competitive landscape report
- SCTB35 injection updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI